139 related articles for article (PubMed ID: 23355589)
1. Rifampicin pharmacokinetics in extreme prematurity to treat congenital tuberculosis.
Le Doare K; Barber N; Doerholt K; Sharland M
BMJ Case Rep; 2013 Jan; 2013():. PubMed ID: 23355589
[TBL] [Abstract][Full Text] [Related]
2. Anthropometric and Genetic Factors Associated With the Exposure of Rifampicin and Isoniazid in Mexican Patients With Tuberculosis.
Huerta-García AP; Medellín-Garibay SE; Salazar-González RA; Ortiz-Álvarez A; Magaña-Aquino M; Rodríguez-Pinal CJ; Portales-Pérez DP; Romano-Moreno S; Milán-Segovia RDC
Ther Drug Monit; 2019 Oct; 41(5):648-656. PubMed ID: 30939588
[TBL] [Abstract][Full Text] [Related]
3. Preterm Twins Born to a Mother with Miliary Tuberculosis: Importance of Early Recognition and Prompt Response in Infection Control to Manage Congenital Tuberculosis Exposure in a Neonatal Intensive Care Unit.
Ryu BH; Baek EH; Kim DH; Kim SE; Kim HJ; Cho OH; Hong SI; Do HJ; Park CH
Jpn J Infect Dis; 2021 Mar; 74(2):97-101. PubMed ID: 32741929
[TBL] [Abstract][Full Text] [Related]
4. Delayed death from pulmonary tuberculosis: unsuspected subtherapeutic drug levels.
Morehead RS
South Med J; 2000 May; 93(5):507-10. PubMed ID: 10832953
[TBL] [Abstract][Full Text] [Related]
5. Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers.
Padgaonkar KA; Revankar SN; Bhatt AD; Vaz JA; Desai ND; D'Sa S; Shah V; Gandewar K
Int J Tuberc Lung Dis; 1999 Jul; 3(7):627-31. PubMed ID: 10423226
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes.
Labana S; Pandey R; Sharma S; Khuller GK
Int J Antimicrob Agents; 2002 Oct; 20(4):301-4. PubMed ID: 12385689
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India.
Hemanth Kumar AK; Kannan T; Chandrasekaran V; Sudha V; Vijayakumar A; Ramesh K; Lavanya J; Swaminathan S; Ramachandran G
Int J Tuberc Lung Dis; 2016 Sep; 20(9):1236-41. PubMed ID: 27510252
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and safety evaluation of the use of ciprofloxacin on an isoniazid-rifampicin regimen in rabbits.
Padilha EC; Pires RV; Filho MA; de Pontes Machado DV; Baldan HM; Davanço MG; Campos ML; Brunetti IL; Peccinini RG
Biopharm Drug Dispos; 2012 Dec; 33(9):501-9. PubMed ID: 23007681
[TBL] [Abstract][Full Text] [Related]
9. Tuberculous subcutaneous abscesses developing during miliary tuberculosis therapy.
Mert A; Bilir M; Ozturk R; Tabak F; Ozaras R; Tahan V; Senturk H; Aktuglu Y
Scand J Infect Dis; 2000; 32(1):37-40. PubMed ID: 10716075
[TBL] [Abstract][Full Text] [Related]
10. ISONIAZID AND RIFAMPIN PHARMACOKINETICS IN TWO ASIAN ELEPHANTS (ELEPHAS MAXIMUS) INFECTED WITH MYCOBACTERIUM TUBERCULOSIS.
Egelund EF; Isaza R; Alsultan A; Peloquin CA
J Zoo Wildl Med; 2016 Sep; 47(3):868-871. PubMed ID: 27691967
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.
Thee S; Seddon JA; Donald PR; Seifart HI; Werely CJ; Hesseling AC; Rosenkranz B; Roll S; Magdorf K; Schaaf HS
Antimicrob Agents Chemother; 2011 Dec; 55(12):5560-7. PubMed ID: 21968358
[TBL] [Abstract][Full Text] [Related]
12. Rifampicin serum levels in childhood tuberculosis.
Thee S; Detjen A; Wahn U; Magdorf K
Int J Tuberc Lung Dis; 2009 Sep; 13(9):1106-11. PubMed ID: 19723399
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
[TBL] [Abstract][Full Text] [Related]
14. Isoniazid and rifampicin concentrations in children with tuberculosis with either a daily or intermittent regimen: implications for the revised RNTCP 2012 doses in India.
Ranjalkar J; Mathew SK; Verghese VP; Bose A; Rose W; Gupta D; Fleming DH; Mathew BS
Int J Antimicrob Agents; 2018 May; 51(5):663-669. PubMed ID: 29241821
[TBL] [Abstract][Full Text] [Related]
15. Tuberculosis in neonates and infants: epidemiology, pathogenesis, clinical manifestations, diagnosis, and management issues.
Skevaki CL; Kafetzis DA
Paediatr Drugs; 2005; 7(4):219-34. PubMed ID: 16117559
[TBL] [Abstract][Full Text] [Related]
16. [Sterilizing activity of the main drugs on the mouse experimental tuberculosis (author's transl)].
Grosset J; Truffot C; Fermanian J; Lecoeur H
Pathol Biol (Paris); 1982 Jun; 30(6):444-8. PubMed ID: 6810288
[TBL] [Abstract][Full Text] [Related]
17. Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus.
Kumar AK; Chandrasekaran V; Kannan T; Murali AL; Lavanya J; Sudha V; Swaminathan S; Ramachandran G
Eur J Clin Pharmacol; 2017 Jan; 73(1):65-70. PubMed ID: 27651240
[TBL] [Abstract][Full Text] [Related]
18. Connatal tuberculosis in a very premature infant.
Chang ML; Jou ST; Wang CR; Chung MT; Lai SH; Wong KS; Huang YC; Chou YH
Eur J Pediatr; 2005 Apr; 164(4):244-7. PubMed ID: 15616826
[TBL] [Abstract][Full Text] [Related]
19. The effect of pyrazinamide and rifampicin on isoniazid metabolism in rats.
De Rosa HJ; Baldan HM; Brunetti IL; Ximenes VF; Machado RG
Biopharm Drug Dispos; 2007 Sep; 28(6):291-6. PubMed ID: 17571294
[TBL] [Abstract][Full Text] [Related]
20. Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption.
Ellard GA; Fourie PB
Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S301-8; discussion S317-21. PubMed ID: 10593709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
